<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741351</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2007-005279-32</org_study_id>
    <secondary_id>AIFA FARM6FKJKK</secondary_id>
    <nct_id>NCT00741351</nct_id>
  </id_info>
  <brief_title>Anesthesiological Strategies in Elective Craniotomy</brief_title>
  <acronym>Neuromorfeo</acronym>
  <official_title>Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Gerardo di Monza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol, NeuroMorfeo, aims to assess equivalence between volatile and intravenous
      anesthetics for neurosurgical procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based on an
      equivalence design. Patients aged between 18 and 75 years, scheduled for a elective
      craniotomy for supratentorial lesion without signs of intracranial hypertension, in good
      physical state evaluated with the ASA (I-III) and Glasgow Coma Scale (GCS) equal to 15, will
      be randomly assigned to one of three anesthesiological strategies (two VA arms, sevoflurane +
      fentanyl or sevoflurane + remifentanil, and one IA, propofol + remifentanil). The equivalence
      between intravenous and volatile-based neuroanesthesia will be evaluated by comparing the
      intervals required to reach, after anesthesia discontinuation, a modified Aldrete score ≥ 9
      (primary end-point). Two statistical comparisons have been planned: 1) sevoflurane + fentanyl
      vs. propofol + remifentanil; 2) sevoflurane + remifentanil vs. propofol + remifentanil.

      Secondary end-points include: an assessment of neurovegetative stress based on (a)
      measurement urinary catecholamines and plasma and urinary cortisol and (b) estimate of
      sympathetic/parasympathetic balance by power spectrum analyses of electrocardiographic
      tracings recorded during anesthesia; intraoperative adverse events (i.e. hypotension,
      hypertension, requirement of osmotic agents or/and hyperventilation for controlling brain
      swelling); evaluation of surgical field; postoperative adverse events (as seizures, cough,
      shivering, agitation, postoperative hematoma and postoperative pain); patient's satisfaction
      and an analysis of costs.

      411 patients will be recruited in 14 different Italian centers during an 18-month period.

      The recruitment started December 20th, 2007 and up to 11th March 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-anesthesia awaking time, assessed as the interval (min:sec)required to reach an ALDRETE score ≥ 9</measure>
    <time_frame>From estubation to aldrete score ≥ 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurovegetative stress</measure>
    <time_frame>From induction of anesthesia to 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and post-operative adverse events assessment</measure>
    <time_frame>From induction of anesthesia to 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain relaxation evaluated by a blinded neurosurgeon</measure>
    <time_frame>From induction of anesthesia to 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction</measure>
    <time_frame>From induction of anesthesia to 24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of the three strategies</measure>
    <time_frame>From induction of anesthesia to end of surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Anesthesia</condition>
  <condition>Craniotomy</condition>
  <condition>Neurosurgery</condition>
  <arm_group>
    <arm_group_label>IF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane (Inhalation)+Fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane (Inhalation)+Remifentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol (Endovenous)+ Remifentanyl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane + Fentanyl</intervention_name>
    <description>Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary</description>
    <arm_group_label>IF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane + Remifentanyl</intervention_name>
    <description>Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary</description>
    <arm_group_label>IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol + Remifentanyl</intervention_name>
    <description>Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary</description>
    <arm_group_label>ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient scheduled for elective intracranial surgery under general anesthesia for a
             supratentorial mass lesion in the next 24 hours;

          -  Physical state, evaluated with the ASA (American Society of Anesthesiologists )
             classification I (normal healthy patient), II (patient with mild systemic disease), or
             III (patient with severe systemic disease);

          -  Age 18-75 years;

          -  Normal preoperative level of consciousness, i.e. Glasgow Coma Scale (GCS) = 15;

          -  No signs of intracranial hypertension.

        Exclusion criteria:

          -  Severe cardiovascular pathology, as uncontrolled arterial hypertension, documented
             reduced coronary reserve.

          -  Renal or liver disease precluding the use of either anesthetic technique.

          -  Pregnancy .

          -  Known allergies to any anesthetic agent.

          -  Reduced preoperative level of consciousness, i.e.

          -  Glasgow Coma Scale (GCS) &lt; 15.

          -  Body weight greater than 120 kg.

          -  History of drug abuse or psychiatric conditions.

          -  Documented disturbance of the hypothalamic region.Refusal to sign consent form.

          -  Participation in other clinical trials.

          -  Delayed awakening, because, due to the location or size of the lesion, postoperative
             sedation and mechanical ventilation are planned.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Citerio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera San Gerardo Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Pesenti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Università delgi Studi Milano Bicocca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Grazia Franzosi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Latini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Consorziale di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione San Raffaele Milano</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricerche Farmacologiche Mario Negri - Dipartimento di Ricerca Cardiovascolare-</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carità di Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Padova</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;A. Gemelli&quot; Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;Umberto I&quot; Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco Torino</name>
      <address>
        <city>Turin</city>
        <zip>10057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San giovanni Battista Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi Varese</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hans P, Bonhomme V. Why we still use intravenous drugs as the basic regimen for neurosurgical anaesthesia. Curr Opin Anaesthesiol. 2006 Oct;19(5):498-503. Review.</citation>
    <PMID>16960481</PMID>
  </reference>
  <reference>
    <citation>Todd MM, Warner DS, Sokoll MD, Maktabi MA, Hindman BJ, Scamman FL, Kirschner J. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology. 1993 Jun;78(6):1005-20.</citation>
    <PMID>8512094</PMID>
  </reference>
  <reference>
    <citation>Engelhard K, Werner C. Inhalational or intravenous anesthetics for craniotomies? Pro inhalational. Curr Opin Anaesthesiol. 2006 Oct;19(5):504-8. Review.</citation>
    <PMID>16960482</PMID>
  </reference>
  <reference>
    <citation>Magni G, Baisi F, La Rosa I, Imperiale C, Fabbrini V, Pennacchiotti ML, Rosa G. No difference in emergence time and early cognitive function between sevoflurane-fentanyl and propofol-remifentanil in patients undergoing craniotomy for supratentorial intracranial surgery. J Neurosurg Anesthesiol. 2005 Jul;17(3):134-8.</citation>
    <PMID>16037733</PMID>
  </reference>
  <reference>
    <citation>Talke P, Caldwell JE, Brown R, Dodson B, Howley J, Richardson CA. A comparison of three anesthetic techniques in patients undergoing craniotomy for supratentorial intracranial surgery. Anesth Analg. 2002 Aug;95(2):430-5, table of contents.</citation>
    <PMID>12145066</PMID>
  </reference>
  <reference>
    <citation>Gomberg-Maitland M, Frison L, Halperin JL. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J. 2003 Sep;146(3):398-403.</citation>
    <PMID>12947355</PMID>
  </reference>
  <reference>
    <citation>Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth. 1995 Feb;7(1):89-91.</citation>
    <PMID>7772368</PMID>
  </reference>
  <reference>
    <citation>Balakrishnan G, Raudzens P, Samra SK, Song K, Boening JA, Bosek V, Jamerson BD, Warner DS. A comparison of remifentanil and fentanyl in patients undergoing surgery for intracranial mass lesions. Anesth Analg. 2000 Jul;91(1):163-9.</citation>
    <PMID>10866905</PMID>
  </reference>
  <reference>
    <citation>Del Gaudio A, Ciritella P, Perrotta F, Puopolo M, Lauta E, Mastronardi P, De Vivo P. Remifentanil vs fentanyl with a target controlled propofol infusion in patients undergoing craniotomy for supratentorial lesions. Minerva Anestesiol. 2006 May;72(5):309-19. English, Italian.</citation>
    <PMID>16675939</PMID>
  </reference>
  <reference>
    <citation>Klingstedt C, Giesecke K, Hamberger B, Järnberg PO. High- and low-dose fentanyl anaesthesia: circulatory and plasma catecholamine responses during cholecystectomy. Br J Anaesth. 1987 Feb;59(2):184-8.</citation>
    <PMID>3828169</PMID>
  </reference>
  <reference>
    <citation>Nishiyama T, Yamashita K, Yokoyama T. Stress hormone changes in general anesthesia of long duration: isoflurane-nitrous oxide vs sevoflurane-nitrous oxide anesthesia. J Clin Anesth. 2005 Dec;17(8):586-91.</citation>
    <PMID>16427527</PMID>
  </reference>
  <reference>
    <citation>Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000 Jul;85(1):109-17. Review.</citation>
    <PMID>10927999</PMID>
  </reference>
  <reference>
    <citation>Bent JM, Paterson JL, Mashiter K, Hall GM. Effects of high-dose fentanyl anaesthesia on the established metabolic and endocrine response to surgery. Anaesthesia. 1984 Jan;39(1):19-23.</citation>
    <PMID>6696213</PMID>
  </reference>
  <reference>
    <citation>Heesen M, Deinsberger W, Dietrich GV, Detsch O, Boldt J, Hempelmann G. Increase of interleukin-6 plasma levels after elective craniotomy: influence of interleukin-10 and catecholamines. Acta Neurochir (Wien). 1996;138(1):77-80.</citation>
    <PMID>8686529</PMID>
  </reference>
  <reference>
    <citation>Ledowski T, Bein B, Hanss R, Paris A, Fudickar W, Scholz J, Tonner PH. Neuroendocrine stress response and heart rate variability: a comparison of total intravenous versus balanced anesthesia. Anesth Analg. 2005 Dec;101(6):1700-5.</citation>
    <PMID>16301244</PMID>
  </reference>
  <reference>
    <citation>Guzzetti S, Borroni E, Garbelli PE, Ceriani E, Della Bella P, Montano N, Cogliati C, Somers VK, Malliani A, Porta A. Symbolic dynamics of heart rate variability: a probe to investigate cardiac autonomic modulation. Circulation. 2005 Jul 26;112(4):465-70. Epub 2005 Jul 18. Erratum in: Circulation. 2005 Aug 30;112(9):e122. Mallani, Alberto [corrected to Malliani, Alberto].</citation>
    <PMID>16027252</PMID>
  </reference>
  <reference>
    <citation>Olsen KS, Pedersen CB, Madsen JB, Ravn LI, Schifter S. Vasoactive modulators during and after craniotomy: relation to postoperative hypertension. J Neurosurg Anesthesiol. 2002 Jul;14(3):171-9.</citation>
    <PMID>12172288</PMID>
  </reference>
  <reference>
    <citation>Leslie K, Troedel S. Does anaesthesia care affect the outcome following craniotomy? J Clin Neurosci. 2002 May;9(3):231-6. Review.</citation>
    <PMID>12093125</PMID>
  </reference>
  <reference>
    <citation>Hall GM, Young C, Holdcroft A, Alaghband-Zadeh J. Substrate mobilisation during surgery. A comparison between halothane and fentanyl anaesthesia. Anaesthesia. 1978 Nov-Dec;33(10):924-30.</citation>
    <PMID>727414</PMID>
  </reference>
  <reference>
    <citation>Fung D, Cohen M, Stewart S, Davies A. Can the Iowa Satisfaction with Anesthesia Scale be used to measure patient satisfaction with cataract care under topical local anesthesia and monitored sedation at a community hospital? Anesth Analg. 2005 Jun;100(6):1637-43.</citation>
    <PMID>15920188</PMID>
  </reference>
  <reference>
    <citation>Citerio G, Stocchetti N, Cormio M, Beretta L. Neuro-Link, a computer-assisted database for head injury in intensive care. Acta Neurochir (Wien). 2000;142(7):769-76.</citation>
    <PMID>10955671</PMID>
  </reference>
  <reference>
    <citation>Piper I, Citerio G, Chambers I, Contant C, Enblad P, Fiddes H, Howells T, Kiening K, Nilsson P, Yau YH; BrainIT Group. The BrainIT group: concept and core dataset definition. Acta Neurochir (Wien). 2003 Aug;145(8):615-28; discussion 628-9.</citation>
    <PMID>14520540</PMID>
  </reference>
  <reference>
    <citation>Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006 Mar 8;295(10):1152-60. Erratum in: JAMA. 2006 Oct 18;296(15):1842.</citation>
    <PMID>16522836</PMID>
  </reference>
  <reference>
    <citation>Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006 Mar 8;295(10):1147-51.</citation>
    <PMID>16522835</PMID>
  </reference>
  <reference>
    <citation>Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006 Jul 4;145(1):62-9.</citation>
    <PMID>16818930</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Gerardo di Monza</investigator_affiliation>
    <investigator_full_name>Dott. Giuseppe Citerio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Neurosurgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

